INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51001, 17825, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51002, 18099, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51003, 18890, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51004, 18892, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51005, 19827, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51006, 20026, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51007, 20027, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51008, 27484, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51009, 27485, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51010, 27486, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51011, 28793, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51012, 28794, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51013, 28843, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51014, 28844, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51015, 29713, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51016, 29714, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51017, 29715, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51018, 30137, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51019, 30613, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51020, 30614, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51021, 31533, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51022, 32311, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51023, 727, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51024, 4751, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51025, 4752, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51026, 7996, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51027, 11962, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51028, 12664, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51029, 12665, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51030, 17824, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51031, 17825, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51032, 18099, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51033, 18890, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51034, 18892, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51035, 19827, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51036, 20026, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51037, 20027, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51038, 27484, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51039, 27485, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51040, 27486, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51041, 28793, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51042, 28794, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51043, 28843, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51044, 28844, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51045, 29713, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51046, 29714, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51047, 29715, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51048, 30137, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51049, 30613, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51050, 30614, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51051, 31533, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51052, 32311, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51053, 810, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51054, 812, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51055, 814, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51056, 817, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51057, 2432, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51058, 2932, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51059, 4632, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51060, 4633, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51061, 4635, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51062, 4636, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51063, 5362, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51064, 5363, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51065, 6823, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51066, 6825, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51067, 10381, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51068, 11825, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51069, 14254, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51070, 14256, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51071, 14259, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51072, 18355, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51073, 19600, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51074, 19605, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51075, 24714, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51076, 24715, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51077, 24718, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51078, 26877, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51079, 810, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51080, 812, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51081, 814, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51082, 817, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51083, 2432, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51084, 2932, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51085, 4632, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51086, 4633, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51087, 4635, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51088, 4636, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51089, 5362, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51090, 5363, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51091, 6823, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51092, 6825, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51093, 10381, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51094, 11825, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51095, 14254, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51096, 14256, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51097, 14259, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51098, 18355, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51099, 19600, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51100, 19605, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', '', 'DDInter', 0);
